Kinetic modeling is important to understand how to obtain the best quantitative measurement of novel tracers in the organ of interest.
A new kinetic model for a PET imaging tracer may help significantly improve both the diagnosis of and treatment response for patients with transthyretin (ATTR) cardiac amyloidosis, according to research presented at the 2023 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting, taking place June 24-27, 2023 in Chicago.
Researchers led by Qiong Liu, a PhD student at Yale University, set out to determine a fully quantitative model to better measure myocardial uptake of 18F-flutemetamol, a tracer that has shown promise to detect ATTR cardiac amyloidosis in PET imaging. Current methods that utilize static data analysis are limited due to time constraints related to tracer washout from the myocardium, resulting in a limited or incomplete readout.
Liu and colleagues studied data from six patients with ATTR cardiac amyloidosis who underwent one hour of dynamic PET/CT after receiving 18F-flutemetamol tracer via bolus. They tested various compartmental models against 34 reconstructed dynamic images that included image-derived input functions and myocardium time activity curves. Population-based whole blood-to-plasma ratio correction and plasma metabolite correction were derived from a previous study. They examined both Patlak and Logan plots and tested one-tissue (1T), two-tissue (2T) reversible, and 2T irreversible compartmental models with blood volume estimation. Parametric images of the the equilibrium myocardium to plasma ratio (VT) were then generated.
Liu and colleagues found that the 2T reversible model best quantified the kinetics of the PET tracer, with the VT values generated by the 2T reversible compartmental model consistent with VT values calculated by the Logan plot (P =.99). The mean VT values of the six patients was 2.61 ± 0.47 with plasma metabolite correction and population-based whole blood-to-plasma ratio correction, which was 118% ± 30% higher than those without corrections. The Logan plot best identified the volume of distribution parameter from the first 30-minutes of dynamic scan (mean VT values, 2.35 ± 0.32 (P =.01), 10.1% ± 5.5% lower than 60-minute data) as a quantitative parameter that could potentially improve diagnosis and evaluation of treatment effect in this patient population.
“These findings suggest that commonly employed semiquantitative methodologies, such as standardized uptake values used for 18F-FDG, are notoptimal for 18F-flutemetamol," Liu said in a statement. "Using parametric modeling to fully quantify volume of distribution may provide clinicians with a more accurate and robust method for assessing the presence and progression of amyloid plaques in the myocardium, ultimately improving patient care."
Click here for more coverage of SNMMI 2023.
FDA Clears New Centiloid Scoring and Tau PET Quantification Tools
October 20th 2024Offering standardized assessment of amyloid plaque and insights on tau protein tangles, the newly clearly FDA features of Centiloid scoring and tau PET quantification with syngo.PET Cortical Analysis software may facilitate diagnosis of Alzheimer’s disease.
Radiology ‘Game-Changer’: FDA Approves PET Agent for Enhanced Detection of Coronary Artery Disease
September 28th 2024Offering higher diagnostic efficacy than SPECT imaging for coronary artery disease (CAD) detection, the PET myocardial perfusion imaging agent Flyrcado™ (flurpiridaz F 18, GE HealthCare) provides unit dose availability and effectiveness in imaging patients with high BMI.